Market Overview

Stifel Nicolaus Initiates Coverage on Chemocentryx at Buy, Announces PT of $16

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for CCXI

DateFirmActionFromTo
Dec 2013CitigroupDowngradesBuyNeutral
Sep 2013JP MorganDowngradesOverweightNeutral
May 2013Stifel NicolausMaintainsBuy

View More Analyst Ratings for CCXI
View the Latest Analyst Ratings

Posted-In: Price Target Initiation Analyst Ratings

 

Related Articles (CCXI)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→